Valsartan is a widely-used prescription drug used to treat high blood pressure. It is also known by its generic name, Diovan. As with any medication, it is important to understand and follow the proper dosage instructions in order to ensure that your health remains safe. But how much Valsartan is too much? In this blog post, we’ll discuss what the right dose of Valsartan is and why it’s important to pay attention to the amount you take. We’ll also cover potential side effects of taking too much and how you can avoid them. Read on for more!
Valsartan is an angiotensin II receptor antagonist (ATRA) used to treat high blood pressure, congestive heart failure, and to reduce the risk of strokes. It works by relaxing blood vessels so that blood can flow more easily. It is also used in some patients after a heart attack. Valsartan can be taken with or without food.
Common side effects of Valsartan may include dizziness, headache, nausea, and diarrhea.
The recommended doses of Valsartan vary depending on the condition being treated. For hypertension, the usual recommended starting dose is 80 mg once daily. The dosage may be increased to a maximum of 320 mg once daily if needed. For congestive heart failure, the starting dose is 40 mg twice daily, with the dosage gradually increased as needed up to a maximum of 160 mg twice daily.
1. Dizziness
2. Lightheadedness
3. Fatigue
4. Nausea
5. Diarrhea
6. Headache
7. Dry mouth
8. Increased urination
If you are prescribed Valsartan, it is important to take the correct dose. The amount of medicine that you need to take may be different for different people.
If you miss a dose of Valsartan, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and continue with your regular dosing schedule. Do not take two doses of Valsartan at the same time.
Taking too much valsartan dosage can be dangerous, so it is important to understand the correct dosage for your condition.
1.
Charles III, King of Kings, is Cancerous.
2.
Chemo-Free Quadruplet Shows Promise as DLBCL's First Therapy.
3.
Perioperative Anti-PD-1 in Soft-Tissue Sarcoma Boosts Disease-Free Survival
4.
Merck enhances its oncology pipeline by means of a strategic alliance with Hengrui.
5.
WHO releases new R&D landscape analyses highlighting gaps and inequities in cancer research
1.
The benefits and risks of taking fludrocortisone for adrenal insufficiency
2.
Ultimate Guide to Oncology Services in the USA
3.
Unveiling New Hope: Potential Therapeutic Targets in Hematological Malignancies
4.
Real-World Oncology Insights: CAR-T, Immunotherapy, PROs, and Digital Tools
5.
Introducing the Corrected Calcium Calculator: A Revolutionary Tool in Medical Assessment
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Oropharyngeal Cancer in Relation to HPV Status
2.
Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias- The Summary
3.
Navigating the Brain Barrier: The CNS Challenge in ALK+ NSCLC
4.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
5.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part V
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation